Research and Markets (http://www.researchandmarkets.com/research/qj88sh/emixustat) has announced the addition of the "Emixustat (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering. Currently the ... Individual.com, 1 month ago
Emixustat (Macular Edema and Macular Degeneration) Industry Report- Forecast and Market Analysis to 2023 - Digital Journal, 1 month ago
Research and Markets: Emixustat Hydrochloride (formerly known as ACU-4429) Macular Edema and Macular Degeneration Drug Forecast and Market Analysis to 2023 - TMC Net, 1 month ago
1 images for "Emixustat Hydrochloride"
SEATTLE--(BUSINESS WIRE)-- Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic ...CNBC, 1 month ago Acucela Files Opposition to SBI/Kubota Motion to Compel Company to Call Special Shareholders Meeting CEOWorld Magazine, 1 month ago Acucela to Hold 2015 Annual Meeting of Shareholders on June 8, 2015 CEOWorld Magazine, 1 month ago
Diabetic Macular Edema Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb The report "Diabetic Macular Edema - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Diabetic Macular Edema. Diabetic macular edema is swelling of the retina in diabetes mellitus due to ...Crawford Financial Planning, 1 month ago
on your WebpageAdd Widget >Get your members hooked!